What is the current stock price of HUTCHMED (China) Limited (HCM)?

As of the latest market data, HUTCHMED (China) Limited (HCM) is trading at $11.72. The stock has seen a loss of -0.26% today.

Does HUTCHMED (China) Limited (HCM) pay a dividend?

Based on current data, HUTCHMED (China) Limited does not have a confirmed active dividend policy.

What is the market cap of HUTCHMED (China) Limited?

The current market capitalization of HUTCHMED (China) Limited (HCM) is approximately unavailable.

HCM

HUTCHMED (China) Limited·Healthcare

11.72

0.255%(−0.03)

Close Price

13.84

18.089%(+2.12)

Pre-Market

Last Updated: — ET

52W L: $11.5152W H: $19.50

HCM NEWS

globenewswire.com

6d ago

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.

prnewswire.com

May 21

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes

globenewswire.com

May 21

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study

globenewswire.com

May 20

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites

HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership

globenewswire.com

May 18

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms

HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations

globenewswire.com

May 13

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

Company Profile

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1,811

IPO Date

2016-03-16

Beta

0.38

Websitewww.hutch-med.com↗